Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 21 for “"NRAS"”.
-
Impact of Kras/Nras Mutational Heterogeneity On Clinical Outcomes In Colorectal Cancer
… Mutations in <em>KRAS/NRAS</em> (<em>RAS</em>) predict a lack of benefit from anti-EGFR agents in metastatic colorectal cancer (mCRC). As next generation sequencing (NGS) has advanced, we are discovering atypical and low allele frequency mutations. We aimed to evaluate …
-
Oncogenic roles of RAS in acute myeloid leukemia cooperated with Mll-AF9.
… mastocytosis was developed in Vav-tTA ; TRE-NRAS G12V transgenic mice without detectable other diseases. We assayed Vav-tTA -driven luciferase expression in hematopoietic cells including bone marrow-derived mast cells (BMMC) and CD34 positive hematopoietic progenitor cells (HPC) as well as …
-
Nucleic acid clamp-mediated transcriptional and translational modulation of oncogenes via the stabilization of G-quadruplexes
… this NA-clamp approach on MYC promoter G4 and NRAS 5’-UTR G4. Silencing MYC and NRAS expression has been demonstrated to be an effective approach to induce apoptosis of lymphoma and breast cancer, and melanoma, respectively. Targeting and stabilizing G4 structures formed in the promoter of MYC …
-
Design and analysis of pattern null reconfigurable antennas
… of pattern null reconfigurable antennas (NRAs). Unlike conventional pattern reconfigurable antennas, NRAs possess the ability to steer their pattern nulls, yielding interference rejection capabilities. While various NRAs exist, the current state of the art has two significant drawbacks, …
-
Identification of transcriptional mechanisms downstream of nf1 gene defeciency in malignant peripheral nerve sheath tumors
… al., 2012).</p> <p>In this study, we modulated NRAS, MEK1/2 and neurofibromin levels in MPNST cell lines and determined the global gene expression changes that were associated with each experimental condition. Furthermore, gene expression changes due to neurofibromin deficiency but independent …
-
Circulating tumour DNA: A non-invasive biomarker for melanoma
… some extent, neuroblastoma RAS viral oncogene (NRAS) mutant ctDNA are utilised to monitor patients during therapy in the research setting (Ascierto et al., 2013a; Girotti et al., 2015; Gray et al., 2015; Sanmamed et al., 2015; Santiago-Walker et al., 2015). Notably, telomerase reverse …
-
A GNAQ/11-driven zebrafish cancer model identifies MITF and YAP as key determinants for uveal melanoma
… which is driven by oncogenic mutation of BRAF or NRAS, UM is driven by oncogenic mutations in GNAQ or GNA11 (>80% of patients). We developed a zebrafish model of UM by expressing GNAQ[superscript Q209L] in the melanocytes of p53-/- zebrafish. In this model, oncogenic GNAQ activates biological …
-
Evaluation of Altered Kras Codon Bias and NOS Inhibition During Lung Tumorigenesis
<p>The small GTPases <italic>HRAS, <italic>NRAS and <italic>KRAS are mutated in approximately one-third of all human cancers, rendering the proteins constitutively active and oncogenic. Lung cancer is the leading cause of cancer deaths worldwide, and more than 20% of human lung cancers harbor …
-
Multicomponent Complexes, Structural Proteomes, Drug Discovery For Cancer Gene Census And SARS CoV-2
… and described in this thesis. Therefore, GTPase NRAS frequently reported mutants such as Q61K/L, G12D, and G13D were studied experimentally to understand the impacts of these mutations on protein structural conformation and function. In addition, hypotheses are presented concerning newly …
-
Therapeutic Targeting Of Bmp2 In Nf1-Deficient Malignant Peripheral Nerve Sheath Tumors (mpnsts)
… therapeutic target in MPNSTs, independent of the NRAS and MEK1/2 regulation. The overall goal of my research was to validate the significance of BMP2 in MPNSTs in novel cellular models, study the combinatorial effects of BMP2 and MEK1/2 inhibition, and use the regulation of BMP2 transcriptional …
-
Assessing the Mutational Landscape of BRAF- and KRAS-Wild Type Colorectal Cancer
… our two cohorts of colorectal cancer patients. NRAS and TP53 mutations, as well as ERBB2, FGFR1, and EGFR amplifications, occurred more frequently in the wild-type cohort than the mutant cohort. We also assessed the number of cases in the wild-type cohort that would be eligible for clinical …
-
Ehrlichia chaffeensis TRP32 is a Nucleomodulin that Regulates Host Gene Expression and Post-Translational Modifications Determine its Localization and Function
… and inflammation such as FOS and JUN, AKT3 and NRAS, and non-coding RNA genes, miRNA 21 and miRNA 142. TRP32 target genes were differentially regulated during infection, and direct repression/activation of these genes by TRP32 was confirmed in vitro with a cellular luciferase reporter assay. …
-
Identification of Tissue and Circulating Biomarkers For Premalignant and Malignant Lesions
… SMAD4, FBXW7, CTNNB1, SYNE1, CDC27, CSMD1, NRAS, RYR3, NALCN, LRP1B, FAT4, ATM, TMPRSS13, SOX9, CSMD3, MED12</em>) which constantly served to separate adenomas from adenocarcinomas were discovered.</p> <p>The Second project focused on exploring differentially expressed genes (DEG) and …
-
Structure Based Drug Design of High Affinity Kras Inhibitors
… There are three isoforms of RAS in cells; HRAS, NRAS and KRAS. We focused on KRAS since it is the most frequently mutated isoform in cancer. To identify novel non-covalent small molecules that bind to mutant KRAS, we conducted a high-throughput virtual screen of drug-like compounds against a …
-
Investigating the Role of ZNF384 Rearrangements in Acute Leukemia
… with common concomitant lesions, such as NRAS G12D, was necessary in order to develop a fully penetrant mouse leukemia in vivo. In contrast, ZNF384 fusions alone drive B/myeloid leukemia when expressed in human hematopoietic stem and progenitor cells and transplanted into NSG-SGM3 mice, …
-
Evaluating Cost Effectiveness of Precision Cancer Medicine Approaches and The Economic Burden of Colorectal Cancer
… cost effectiveness of testing of KRAS/NRAS mutational status for guiding cetuximab or panitumumab therapy is inconclusive.<br/><br/>Overall, the systematic review revealed that there was a paucity of cost-effectiveness studies in CRC to support biomarker-enriched PCM …
-
Single Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms
… in one case, a patient showed an expansion of NRAS mutation accompanied by an erythroid shift. In another case, a patient exhibited the acquirement of KRAS and FLT3 mutations accompanied by a monocytic shift.</p> <p> To delve into the mechanisms driving these transitions, we profiled the …
-
Genetic investigation of South Africans with the Noonan Syndrome phenotype using targeted next generation sequencing
… A2ML1, BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, SOS1 and SPRED1. Results: Of the 26 patients included, 50% had a family history suggestive of NS. The median age at diagnosis was4.5 years (range: 1month-51years). Individuals of mixed-race ancestry were most …
-
Molecular signatures underlying the tumourigenic transformation in a CEBPA mutated model of leukaemia
… pathway, including mutations in the Kras, Nras, Ptpn11, Flt3 and Cbl genes. This result demonstrated that in this model, a single C-terminal CEBPA mutation alone is not sufficient to induce disease and requires secondary drivers. Intriguingly, secondary mutations recapitu- lated the most …
Page 1 of 2